A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine. |
Youn Jung Park, Keun Suk Yang, Hong Soon Jung, Hee Chul Nam, Seung Hye Jung, Boo Gyoung Kim, Ka Young Kim, Jung Ho Kim, Young Ok Kim, Yu Seon Yun |
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. junpearl19@naver.com |
|
Abstract |
Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential. |
Key Words:
Hemolytic-Uremic Syndrome, Gemcitabine, Lung Neoplasms |
|